 전영우 교수 E-mail : 준비중 |
|
연구분야 신재생의료 CAR-T,면역세포치료제 림프종의 세포기원 연구 림프종의 미세종양환경 연구 동종조혈모세포 이식 후 이식편대숙주질환 예방을 위한 Tr1면역세포 치료제연구 동종조혈모세포 이식 후 발생하는 이식편대숙주질환의 기전 중 HMGB1의 역할 |
|
학력사항 - 순천향대학교 의학 학사(2002) - 순천향대학교 내과학 석사(2013) - 가톨릭대학교 내과학 박사(2019) |
|
경력사항 -순천향의과대학 부천병원인턴 (2003) - Mt. Sinai Medical Center, Chicago, IL, Categorical Internal Medicine, Residency(2008~2009) - 순천향의과대학 의료원 내과 전공의 (2009~2013) - 가톨릭대학교 서울성모병원 혈액내과 임상강사 (2013~2015) -가톨릭대학교서울성모병원 혈액내과 임상조교수(2015~2019) -여의도성모병원 혈액내과 임상조교수(2018~2019) - 가톨릭대학교 여의도성모병원 중개의학분자영상연구소 공동연구원(2019~현재) - 가톨릭대학교여의도성모병원 혈액내과 분과장 (2020~현재) -가톨릭대학교 여의도성모병원 림프종센터 조교수(2020~현재) -대한조혈모세포이식학회 정회원(현재) -대한내과학회 정회원 (현재) - 대한암학회 정회원 (현재) - 대한혈액학회 정희원(현재) - 대한독성유전-단백체학회 임원 (현재) |
|
주요 연구물 1. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Prognostic Impact of Interim Positron Emission Tomography in Mantle Cell Lymphoma Patients Treated with Frontline R-CHOP, British Journal of Haematology 2020. 2. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ ,Cho SG. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience, Cancer Medicine 2019. 3. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Risk factors predicting graft- versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non- Hodgkin’s lymphoma, Annals of Hematology (2019). 4. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non- Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation, Clinical Lymphoma, Myeloma & Leukemia (2019). 5. Jeon YW, Lim JY, Im KI, Nam YS, Song YJ, Cho SG. (2018) Enhancement of Graft-versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1-Regulatory T Cells in Bone Marrow Transplant Model. Stem Cells Dev. doi.org/10.1089/scd.2018.0113. 6. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Cho SG , Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. Clinical Lymphoma, Myeloma & Leukemia (2017). 7. Jeon YW, Kim N, Nam YS, Lim JY, Im KI, Lee ES, Cho SG. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine. 2016;78:22–6. 8. Lim JY, Jeon YW, Im KI, Lee ES, Kim N, Nam YS, Cho SG: Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory t cells in collagen-induced arthritis. Scientific reports 2016;6:26851. 9. Jeon YW, Ahn TS, Jeong DJ, Son MW, Jung HI, Park SY, Kim HJ, Bae SB, Kim HJ, Lee MS, Baek MJ. The BRAF mutation is associated with the prognosis in colorectal cancer. J. Cancer Res. Clin. Oncol. 2014;140(11):1863–71. 10. Jeon YW, Yang HJ, Choi BO, Jung SE, Park KS, O JH, Yang SW, Cho SG. Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. EClinicalMedicine 4–5 (2018) 32–42. 11. Jeon YW, Kwak DH, Park SS, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Min WS, Cho SG. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):595-603. doi: 10.1016/j.clml.2017.06.027. 12. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Min WS, Cho SG. Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study. Korean J Intern Med. 2016 Sep;31(5):944-52. 
|
